Sanofi will cap the out-of-pocket cost of its most popular insulin, Lantus, at $35 per month for people with private insurance, the French drugmaker said Thursday. "As of this afternoon, all three of the leading insulin producers in America have agreed to substantially reduce their prices, following my calls to expand my $35 cap for seniors to all Americans," Biden said. ”“We will continue advocating for efforts in Congress and states across the country to ensure insulin is affordable to everyone with diabetes who relies on it to survive,” Murdock said